Dec 17, 2019
Rigel Announces Chief Commercial Officer Transition
Dec 12, 2019
COMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers
Nov 15, 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Nov 07, 2019
Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition
Oct 29, 2019
Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results
Oct 23, 2019
Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call
Oct 18, 2019
Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Oct 16, 2019
Rigel to Host Investor and Analyst Call on October 23, 2019
Sep 23, 2019
Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia
Aug 06, 2019
Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update
Jun 13, 2019
Rigel to Present Two Posters Highlighting Fostamatinib at the 24 Congress of the European Hematology Association (EHA)
May 16, 2019
Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
Mar 04, 2019
Defence Secretary announces £11million boost to chemical defences
Feb 28, 2019
Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Jan 23, 2019
Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
Jan 07, 2019
Rigel Pharmaceuticals Provides Business Update
Jan 03, 2019
Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 05, 2018
Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
Nov 06, 2018
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update
Nov 01, 2018
Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition